| HOME >> BIOLOGY >> TECHNOLOGY |
Carilion Clinic teams up with Retasure
Wake Forest, NC (PRWEB) August 29, 2008 -- Digital Healthcare, a Wake Forest, NC company specializing in risk assessment for diabetics, recently announced that the Carilion Clinic of Virginia has selected the Retasure solution to provide retinal imaging risk assessment to diabetic patients.
Carilion Medical Group is one of the largest physician practices in Virginia, and is the largest primary care group in the state. It consists of more than 200 physicians, Nurse Practitioners and Physician Assistants in 70 offices across western Virginia and the Shenandoah Valley. The practice provides care to more than 2,500 diabetics in the region.
"Carilion Medical Group is a very important healthcare provider in this community," says Scott Sanner, Senior Vice President for Digital Healthcare's North American Operations. "They see a large number of patients at risk for vision loss, but it is estimated that up to half of these patients do not have regular eye exams. Being assessed for retinopathy through their PCP will undoubtedly lead to earlier detection -- and prevention -- of vision loss."
The FDA-approved and HEDIS compliant Retasure program provides a simple, affordable, and non-invasive solution that allows physicians to capture their patients' retinal images during a three to five minute procedure. Images are transmitted over a secure, HIPAA compliant network to an accredited reading center. A state-licensed and board-certified ophthalmologist reviews the images and results are returned to the original physician within 72 hours.
There are an estimated 20 million diabetic patients in the US, but only about half have any retinal assessments, despite a high risk of diabetic retinopathy. The National Eye Institute indicates diabetic retinopathy is the leading cause of blindness among working age American adults.
'/>"/>
| Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved |
Related biology technology :
1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |